clodronic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium metabolism regulator, pharmaceutical aid | 690 | 10596-23-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.60 | g | O |
| 1.50 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.40 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 80 % | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.88 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.64 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 43.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1986 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Osteonecrosis of jaw | 83.23 | 42.19 | 22 | 241 | 34380 | 46651419 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M05BA02 | MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates |
| MeSH PA | D050071 | Bone Density Conservation Agents |
| CHEBI has role | CHEBI:35610 | cytostatic |
| CHEBI has role | CHEBI:50646 | anti-osteoporotics |
Drug Use (View source of the data)
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 0.13 | acidic |
| pKa2 | 4.2 | acidic |
| pKa3 | 5.18 | acidic |
| pKa4 | 9.25 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Enzyme | WOMBAT-PK | |||||||
| ADP/ATP translocase 3 | Enzyme | WOMBAT-PK | |||||||
| ADP/ATP translocase 1 | Transporter | WOMBAT-PK | |||||||
| ADP/ATP translocase 2 | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| N0000166424 | NUI |
| D03545 | KEGG_DRUG |
| C0162357 | UMLSCUI |
| CHEBI:59585 | CHEBI |
| CHEMBL12318 | ChEMBL_ID |
| DB00720 | DRUGBANK_ID |
| D004002 | MESH_DESCRIPTOR_UI |
| 25419 | PUBCHEM_CID |
| 9605 | IUPHAR_LIGAND_ID |
| 4147 | INN_ID |
| 0813BZ6866 | UNII |
| 3350 | RXNORM |
| 003710 | NDDF |
| 387579006 | SNOMEDCT_US |
| 418080006 | SNOMEDCT_US |
| 768528000 | SNOMEDCT_US |
Pharmaceutical products:
None